603811.SH
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 7.24
−2.16%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 827.8M | 812.3M | 714.4M | 671.6M | 655.0M |
| Cost of Revenue | 248.1M | 245.3M | 217.6M | 240.6M | 206.8M |
| Gross Profit | 579.6M | 567.0M | 496.7M | 431.0M | 448.2M |
| Operating Expenses | |||||
| R&D Expense | 49.6M | 44.4M | 47.1M | 47.1M | 44.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 139.7M | 132.5M | 127.9M | 96.3M | 91.1M |
| Selling & Marketing Expense | 196.9M | 195.7M | 182.6M | 152.6M | 180.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 405.3M | 392.7M | 379.9M | 311.7M | 327.3M |
| Cost and Expenses | 653.4M | 638.0M | 597.6M | 552.3M | 534.1M |
| Operating Income (EBIT) | 221.2M | 224.6M | 221.2M | 173.9M | 164.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 220.8M | 223.8M | 218.1M | 174.1M | 163.8M |
| Income Tax Expense | 25.5M | 26.4M | 17.3M | 12.0M | 2.7M |
| Bottom Line | |||||
| Net Income | 193.6M | 195.1M | 200.7M | 162.9M | 161.6M |
| Earnings from Cont. Ops | 195.2M | 197.5M | 200.8M | 162.0M | 161.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 193.6M | 195.1M | 200.7M | 162.9M | 161.6M |
| Per Share | |||||
| Basic EPS | CN¥0.61 | CN¥0.61 | CN¥0.61 | CN¥0.50 | CN¥0.49 |
| Diluted EPS | CN¥0.61 | CN¥0.61 | CN¥0.61 | CN¥0.50 | CN¥0.49 |
| Revenue Per Share | CN¥2.62 | CN¥2.54 | CN¥2.17 | CN¥2.06 | CN¥1.99 |
| Shares | |||||
| Basic Shares Outstanding | 316.4M | 319.9M | 329.0M | 325.8M | 329.8M |
| Diluted Shares Outstanding | 316.4M | 319.9M | 329.0M | 325.8M | 329.8M |
| Profitability Metrics | |||||
| EBITDA | — | 319.5M | 317.4M | 251.9M | 226.8M |
| D&A | — | 94.9M | 96.1M | 78.0M | 62.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026